The original poster, currently owning four investment properties with varying interest rates, contemplates switching to stock investments due to perceived benefits such as higher historical returns and less maintenance burdens compared to real estate. They inquire if there’s a compelling reason not to sell their rental homes and allocate funds into ETFs, suggesting they might be overlooking some crucial aspect of long-term wealth building through stock market investment during Donald Trump’s second presidential term from 2025 to 2029.
Costco has recently partnered with Novo Nordisk to offer the GLP-1 drug Ozempic at $499 per month through their member prescription program, available in over 600 pharmacies without insurance requirements. This move is likened to Costco’s strategy of attracting customers with low-margin, high-traffic items like cheap gas and rotisserie chicken. The initiative could potentially boost pharmacy revenue growth (~15% y/y) and serve as an additional membership hook for Costco, enhancing renewal rates and average spend per member. Although the immediate impact on earnings is uncertain, it strengthens Costco’s competitive advantage. For Novo Nordisk, this partnership expands their U.S. distribution channels ahead of Eli Lilly’s Zepbound launch, supporting both companies’ high valuations (Costco at ~45x earnings and Novo at ~40x). This real-world expansion bolsters their long-term durability for investors.
A lively gathering has occurred at a well-known retail store, with numerous enthusiasts converging to purchase the latest addition to the popular Pokémon series, demonstrating unwavering support for the brand despite its reputation. The event highlights the strong community interest in new game releases.
The original poster argues that Pfizer, despite recent stock declines, is a lucrative buy due to several strategic moves. These include a significant political deal with the White House that eliminates risks like crippling tariffs and price controls, and smart investments in future growth areas such as next-generation cancer drugs via the acquisition of Seagen for $43 billion and entry into the large obesity market. With a low P/E ratio compared to the S&P 500 and a high dividend yield, the poster perceives Pfizer as an undervalued, de-risked innovator offering attractive returns for casual investors or traders.
A user expresses remorse over selling shares of Palantir Technologies in 2021, missing out on significant potential gains. Typically cautious, they admitted to an error in judgment for this particular stock. The post serves as a reminder for investors about the importance of thorough research and long-term commitment when making stock trading decisions.
The stock BURU experienced an unprecedented surge in trading volume last week, with daily averages rising from 20M to peaks of 800M shares. This unusual activity, coupled with heightened community interest on platforms like Reddit and Stocktwits, suggests potential significant developments. Anticipated Q4 catalysts include the Tekne acquisition, participation in major defense events, relisting on the LSE, advancements in blue-laser defense tech, and increasing institutional interest. The original poster speculates BURU might be at the onset of a substantial price adjustment as these events unfold, inviting others to share their perspectives on whether this is early excitement or the dawn of a larger trend in defense and fintech sectors.
The original poster queries the community for their predicted price target for a certain stock, referred to as NVO, which is frequently discussed as a potential value investment. The poster wonders at what price point NVO might be considered no longer a compelling value play, seeking insights from fellow investors or traders. This discussion could be of interest to those in the retail investment sector looking for stock analysis and market sentiment.
An analysis highlights the potential for significant dilution of BURU shares, as evidenced by recent SEC filings. The company has been granted permission to increase its share cap and issue over 650 million new shares, potentially diluting existing shareholders by about 83%. Moreover, approval has been given for issuing more than 19.99% of total shares to Indigo Capital LP via convertible debt, allowing them to sell large blocks continuously without restriction. The original poster advises caution and suggests dilution may have already commenced, advising investors to conduct thorough research before buying BURU stocks.
A casual investor has achieved an impressive 38% return over 4-5 months, equivalent to an annual gain of 8-10%. Seeking advice, they contemplate selling some stocks to accumulate cash, anticipating a potential market pullback. They are open to different perspectives on managing their gains responsibly amidst expectations of future market fluctuations.